查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854772

病毒载体市场按载体类型、产品类型、治疗领域、最终用户、生产阶段和生产规模划分－2025-2032年全球预测

Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，病毒载体市场规模将达到 56 亿美元，复合年增长率为 14.56%。

关键市场统计数据
基准年 2024 18.8亿美元
预计年份：2025年 21.6亿美元
预测年份 2032 56亿美元
复合年增长率 (%) 14.56%

本书简明扼要地介绍了病毒载体生态系统，旨在培养技术、监管和商业性交叉领域的领导者。

病毒载体目前处于前沿生物学和复杂製造过程的交汇点。本导论整合了核心科学模式、关键製造曲折点以及将研究成果转化为临床应用的转化路径。它重点阐述了载体生物学（衣壳选择、嗜性、有效载荷设计）如何与上游细胞培养、转染方法和下游纯化等製程因素相互作用，从而确定整个专案的可行性和时间安排。

在整个研发生命週期中，监管预期和分析要求日益影响设计选择。因此，早期关于载体类型、生产平台和品质属性的决策会层层递进地影响后续的临床可比性和商业供应的风险评估。本节将阐述决策者在选择合作伙伴、投资内部研发能力以及製定临床开发计划时必须权衡的关键营运和策略因素。其目标是为高阶主管、专案负责人和生产规划人员提供一个统一的思维模型，帮助他们明确科学机会与生产可行性和监管要求之间的平衡。

技术创新、监管演变和供应链韧性如何推动病毒载体开发和递送的根本性转变

多种因素共同作用，重塑了病毒载体的格局。载体工程技术的进步——包括改进的衣壳设计、新型血清型和优化的基因组结构——正在拓展组织靶向性和安全性，从而拓宽治疗应用范围。同时，分析方法的进步，例如次世代定序和高解析度杂质分析，使得对产品进行严格的表征以及建立可靠的製程差异比较策略成为可能。

在生产製造方面，模组化生物製程和一次性使用技术正在加快临床试验的周转速度，并降低早期临床试验的资本投入。同时，可扩展层析法化学和替代纯化方法的成熟，使製造商能够应对产量和纯度方面长期存在的挑战。监管机构也不断调整其预期。他们强调稳健的控制策略、杂质的详细表征以及明确的生产变更过渡要求，鼓励申办方更早将监管因素纳入其研发计划。

最后，全球供应链与地缘政治环境正促使相关人员实现采购多元化、关键生产流程在地化，并建立策略供应商关係。这些技术、监管和营运方面的变化正在重新定义可行的商业模式，以及将治疗方法从实验室安全推向临床的时间表。

评估近期关税政策对病毒载体生产投入品供应链、成本和策略采购的累积影响（至2025年）

近期关税措施和贸易政策的变化，给病毒载体生产所需的原材料、设备和专用耗材的采购成本计算引入了新的变数。其累积影响不仅限于直接的零件成本，还波及采购前置作业时间、供应商谈判和库存策略。依赖进口一次性系统、专用层析法树脂或专有设备的工厂，可能会面临更长的认证週期和更高的到岸成本，迫使专案团队评估供应商冗余和在地采购方案。

除了直接采购之外，关税还会影响资本规划决策。评估新建无尘室、灌装包装产能或境内契约製造伙伴关係的公司，现在必须权衡设备进口成本的变化与供应商的供货情况。这促使企业更加关注模组化和移动式生产方式，以减少对重型机械的依赖，并实现产能的逐步扩张。此外，关税带来的波动也凸显了强有力的供应商绩效指标、关键试剂的双重采购以及在保质期和稳定性允许的情况下进行策略性储备的重要性。

最终，虽然关税会造成摩擦和成本压力，但它们也会加速供应链的韧性、关键供应商的伙伴关係，以及向区域製造布局的策略转变，从而平衡风险和营运弹性。

基于对关键细分市场的洞察，突显了技术、临床和商业性差异化在病毒载体市场中创造策略机会的领域。

透过细分，我们可以揭示载体生物学、应用领域、治疗标靶、最终用户、生产阶段和规模等方面的价值和风险所在。依载体类型分类，腺结合病毒、腺病毒、慢病毒和逆转录病毒各有其独特的优缺点。腺相关病毒通常具有较高的安全性和组织嗜性优势，而AAV2、AAV8和AAV9是常用的血清型，但它们在生物分布和预存免疫因素方面存在差异。腺病毒具有高载药量和转导效率，适用于瞬时表达，而慢病毒和逆转录病毒则为持久性、整合性方法（例如体外细胞疗法）奠定了基础。这些差异要求我们制定客製化的生产和分析策略，以使分子特性与治疗目标相符。

应用细分突显了不同的研发和生产路径。细胞疗法、基因疗法、研究和疫苗应用各自拥有独特的流程和监管要求。细胞疗法需要针对特定疗法（例如 CAR-T 细胞、树突状细胞和 TCR-T 细胞）进行载体给药、疗效和安全性测试。基因疗法分为体外和体内两种方法，每种方法对载体纯度和生物分布的要求各不相同。研究应用涵盖基础研究和临床前研究，因此需要灵活的小规模生产和快速的周转时间。同时，预防性和治疗性疫苗计画优先考虑可扩展、经济高效的生产和批次可追溯性。

优先排序在心血管、感染疾病、神经病学、肿瘤学和罕见病等治疗领域进一步细化：心血管项目分为专注于冠状动脉疾病和外周血管疾病的项目，这带来了不同的给药挑战；感染疾病分为针对细菌和病毒的项目，这会影响抗原设计和免疫抗原性管理；神经学计画分为神经退化性疾病，这会影响给药途径和安全性监测；罕见疾病通常是单一疾病，需要高度个人化的产品策略和灵活的生产方式来支持小批量、多品种的生产。

最终用户——生物製药公司、医院和诊所以及研究机构——各自有着不同的需求和对服务的期望。生物製药公司通常需要整合的开发和商业化规模解决方案；医院和诊所优先考虑注射剂型、低温运输物流和即时检测能力；而研发机构则优先考虑调查方法的快速获取和灵活性。将生产阶段划分为下游和上游后发现，对过滤、製剂、纯化、细胞扩增、收穫和转染的投资对营运影响最大。虽然下游纯化（包括层析法和超速离心）仍然是纯度和产量方面的一个瓶颈，但提高上游细胞扩增和转染效率可以直接提高载体的生产力。临床试验需要灵活的、分阶段的生产模式，涵盖I期、II期和III期，而商业性的大规模生产则强调可重复性、成本优化和长期供应协议。

综合来看，这些细分层提供了一个多维地图，可以根据治疗方式、目标人口和商业化途径，优先考虑技术投资、伙伴关係模式和製造布局。

影响美洲、欧洲、中东和非洲以及亚太地区市场准入、製造策略和伙伴关係模式的区域动态

区域因素对病毒载体开发和部署的策略选择有显着影响。在美洲，成熟的生物技术丛集和先进的製造网络支持快速转化途径和对接专业合约研发生产机构（CDMO），但专案团队也必须应对影响商业化策略的区域监管预期和报销环境。在欧洲、中东和非洲，监管协调工作和各国医疗保健体系的差异既为跨国合作创造了机会，也增加了临床试验设计的复杂性。在亚太地区，GMP生产能力的快速扩张、不断壮大的本地科研人才库以及对本土生物製造的政策奖励正在加速产能增长，但申办方必须仔细评估这些因素对区域供应可靠性、本地化程度和知识产权的影响。

临床试验招募动态、目标适应症盛行率和支付方评估标准在不同地区差异显着，这影响着关键性试验的进行地点和打入市场策略的建构。製造地的选择同样受到区域成本结构、人才供应和与患者群体接近性等因素的影响。鑑于这些差异，企业正越来越多地采用混合模式，将区域研发中心与分散式製造地相结合，以平衡成本、监管合规性和患者用药时间。最终，区域策略必须与产品概况、临床设计和商业准入计画紧密结合，以确保从研发到分销的顺利过渡。

透过对病毒载体生态系统中竞争对手和合作伙伴的分析，重点关注其能力丛集、伙伴关係模式和策略重点。

病毒载体领域的开发人员可根据其核心竞争力进行分类，包括专注于平台工程和衣壳发现的公司、专注于可扩展GMP生产的供应商以及提供端到端开发支援的整合商。平台创新者优先考虑深度分子工程、进阶分析、血清型设计和免疫逃脱策略的智慧财产权组合，通常支援跨多个治疗领域的临床计画。生产专家则强调製程稳健性、高产量上游平台以及能够解决长期瓶颈的下游纯化技术。整合商和CDMO整合了这些能力，提供模组化服务，使申办者能够以可预测的时间表和监管支援加速临床供应。

策略伙伴关係日益普遍，技术授权者与合约研发生产机构 (CDMO) 和学术转化研究团队合作，以降低早期专案的风险并扩大成功候选药物的规模。各公司之间的竞争还包括服务范围、地域覆盖以及管理复杂对比试验的能力。对于寻求从临床供应过渡到商业供应的公司而言，在分析开发、数位化批记录和品质自动化方面的投资是胜利的关键。对于评估合作伙伴的高阶主管而言，在品质文化、资料透明度和供应连续性应急计画方面的一致性是衡量长期可靠性的最重要指标。

为确保病毒载体专案的持续开发、监管合规和商业性化准备，产业领导者应立即实施以下切实可行的建议

优先考虑早期整合规划，将衣壳选择、有效载荷设计和生产策略与监管要求联繫起来。让监管和品质专家参与早期专案决策，可以降低后期出现意外情况的风险，并在需要进行製程变更时简化可比性。同时，投资早期分析深度，以建立可靠的效力和杂质检测方法，从而支持新药临床试验申请（IND）和未来的生产转移。

透过关键耗材的双重采购和确定区域供应商来缩短前置作业时间，从而增强供应链韧性。在可行的情况下，采用模组化或一次性使用的生产元件，以加快临床供应，而无需大量资本投入。作为长期策略，评估混合生产模式，将区域临床供应中心与集中式商业能力结合，以优化成本并确保患者获得所需药品。

我们协商的伙伴关係协议包含明确的品质指标、资料存取条款以及应对供应中断的紧急条款。最后，透过及早与市场进入和医学事务部门接洽，明确证据产生需求和患者准入途径，我们将商业计划与临床开发相协调，确保从监管部门核准到临床应用的顺利过渡。

在病毒载体领域，为获得可靠、可重复、决策层面的见解而采用的调查方法和途径

本研究整合了来自行业专家的访谈、监管指南的定性分析以及技术文献，以三角验证病毒载体开发对营运和策略的影响。一级资讯来源包括製程开发、分析科学、品质和商业部门的专家，从而提供了对製程瓶颈、技术应用和伙伴关係行为的综合视角。二级资讯来源则利用同侪审查的研究、监管指南文件和公开资讯来支持技术说明并检验观察到的行业趋势。

透过定性洞察和技术可行性的交叉检验，例如将上游产量与说明精炼限制条件检验，以评估实际製程产能，从而实现分析的严谨性。调查方法优先考虑证据来源的透明度，明确区分基于专家判断的结论和已公开的文件。文中贯穿对局限性和敏感性的讨论，以支持负责任的解读，并在必要时指导后续原始数据的收集。

综合各项结论，重申策略重点，并聚焦在对媒介传播成功至关重要的操作槓桿。

一个根本性的教训是，仅靠科学进步并不能保证专案成功。成功的病毒载体专案取决于载体选择和有效载荷设计与可扩展生产流程的匹配，早期引入严谨的分析方法，以及建立能够提供技术支援和稳定供应的伙伴关係关係。采用模组化生产方法、投资深入的分析研发并积极管理供应商风险的机构，更有可能将前景广阔的生物科学成果转化为可靠的临床和商业供应。

随着生态系的成熟，领导者应将能力建构视为策略重点，而非事后考量。这意味着要投入资源用于品质体系、流程表征和策略供应商关係，同时保持灵活性，以适应不断变化的监管预期和地缘政治贸易动态。简而言之，创造永续价值的关键在于平衡科学创新与营运纪律。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 改进腺结合病毒衣壳以实现靶向体内基因递送
  • 扩展连续生物製程平台以提高病毒载体生产能力
  • 将一次性生物反应器技术整合到可扩展的慢病毒载体生产系统中
  • 一种用于病毒载体基因表现中可调控启动子的新型合成生物学方法
  • 合约生产商与生技公司之间的策略合作加速了病毒载体供应链的韧性
  • 为实现病毒载体疗法的全球临床试验核准，监管协调工作正在进行中。
  • 开发编码mRNA的病毒载体，以快速应对新兴感染疾病疫情
  • 在病毒载体纯化工作流程中实施高阶分析和人工智慧驱动的流程监控

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按载体类型分類的病毒载体市场

  • 腺结合病毒
    • AAV2
    • AAV8
    • AAV9
  • 腺病毒
  • 慢病毒
  • 逆转录病毒

第九章 按应用分類的病毒载体市场

  • 细胞疗法
    • Car T
    • 树突状细胞
    • TCR T
  • 基因治疗
    • 体外
    • In vivo
  • 研究
    • 基础研究
    • 临床前研究
  • 疫苗
    • 预防
    • 治疗

第十章 按治疗领域分類的病毒载体市场

  • 心血管疾病
    • 冠状动脉
    • 週边血管
  • 感染疾病
    • 细菌
    • 病毒
  • 神经系统疾病
    • 神经退化
    • 神经发育
  • 肿瘤学
    • 血液学
    • 固态肿瘤
  • 罕见疾病
    • 单基因

第十一章 病毒载体市场（依最终用户划分）

  • 生物製药公司
  • 医院和诊所
  • 研究所

第十二章 病毒载体市场依生产阶段划分

  • 下游
    • 滤
    • 处方
    • 纯化
      • 层析法
      • 超速离心
  • 上游
    • 细胞增殖
    • 收成
    • 转染

第十三章 病毒载体市场（依生产规模划分）

  • 临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的
    • 全面

第十四章 病毒载体市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 病毒载体市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国病毒载体市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Lonza Group AG
    • Merck KGaA
    • Catalent Inc.
    • WuXi AppTec Co., Ltd.
    • Novasep Holding SAS
    • Oxford BioMedica plc
    • AGC Biologics Inc.
    • Cobra Biologics Ltd.
    • Viralgen SL
Product Code: MRR-957C47F9405B

The Viral Vectors Market is projected to grow by USD 5.60 billion at a CAGR of 14.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.88 billion
Estimated Year [2025] USD 2.16 billion
Forecast Year [2032] USD 5.60 billion
CAGR (%) 14.56%

A concise orientation to the viral vectors ecosystem that prepares leaders for technical, regulatory, and commercial intersections

Viral vectors now sit at the intersection of cutting-edge biology and complex manufacturing. This introduction synthesizes the core scientific modalities, the critical manufacturing inflection points, and the translational pathways that convert research signals into clinical programs. It focuses on how vector biology-capsid selection, tropism, and payload design-interacts with process considerations such as upstream cell culture, transfection methods, and downstream purification to determine overall program feasibility and timelines.

Across the development lifecycle, regulatory expectations and analytical requirements increasingly shape design choices. As a result, early decisions about vector type, production platform, and quality attributes cascade into downstream risk profiles for clinical comparability and commercial supply. Accordingly, this section frames the primary operational and strategic tradeoffs decision-makers must weigh when selecting partners, investing in in-house capabilities, or designing clinical development plans. The aim is to equip executives, program leads, and manufacturing planners with a cohesive mental model that clarifies where scientific opportunity aligns with manufacturing practicality and regulatory acceptability.

How technological innovations, regulatory evolution, and supply chain resilience are driving foundational shifts in viral vector development and delivery

The landscape for viral vectors is being reshaped by several converging forces. Advances in vector engineering-improved capsid design, novel serotypes, and optimized genome constructs-are expanding tissue targeting and safety profiles, which in turn broaden therapeutic applicability. Parallel progress in analytical methods, including next-generation sequencing and high-resolution impurity profiling, has tightened product characterization and enabled more confident comparability strategies between process variants.

On the manufacturing front, modular bioprocessing and single-use technologies are driving faster campaign turnarounds and lower capital exposure for early clinical work. At the same time, the maturation of scalable chromatography chemistries and alternative purification approaches is enabling manufacturers to tackle persistent yield and purity challenges. Regulatory bodies are also evolving their expectations; regulators are emphasizing robust control strategies, detailed characterization of impurities, and clearer bridging requirements for manufacturing changes, prompting sponsors to integrate regulatory thinking earlier into development plans.

Finally, the global supply chain and geopolitical context are encouraging stakeholders to diversify sourcing, localize critical production steps, and cultivate strategic supplier relationships. Together, these technological, regulatory, and operational shifts are redefining viable commercial models and the timelines for safely moving therapies from lab to clinic.

Assessment of cumulative effects from recent tariff policies on supply chains, costs, and strategic sourcing for viral vector production inputs in 2025

Recent tariff measures and trade policy shifts have introduced new variables into the sourcing calculus for raw materials, equipment, and specialized consumables used in viral vector manufacturing. The cumulative impact is felt not only in direct component costs but also in procurement lead times, supplier negotiations, and inventory strategies. Facilities that rely on imported single-use systems, specialized chromatography resins, or proprietary equipment may experience extended qualification timelines and higher landed costs, prompting program teams to reassess supplier redundancy and localized sourcing options.

Beyond direct procurement, tariffs can influence capital planning decisions. Organizations evaluating new cleanroom builds, fill-finish capacity, or onshore contract manufacturing partnerships must now weigh altered equipment import economics and vendor availability. This has sharpened interest in modular and mobile manufacturing approaches that reduce heavy equipment dependence and allow incremental capacity expansion. Furthermore, tariff-driven variability has highlighted the importance of robust supplier performance metrics, dual sourcing for critical reagents, and strategic stockpiling where shelf life and stability allow.

Ultimately, while tariffs add friction and cost pressure, they also accelerate strategic shifts toward supply chain resilience, critical supplier partnerships, and regional manufacturing footprints that balance risk with operational flexibility.

Key segmentation-driven insights that clarify where technical, clinical, and commercial differentiation creates strategic opportunity across the viral vectors market

Segmentation illuminates where value and risk concentrate across vector biology, application areas, therapeutic targets, end users, production stages, and scale. When categorized by vector type, Adeno Associated Virus, Adenovirus, Lentivirus, and Retrovirus each present distinct tradeoffs: Adeno Associated Virus generally offers strong safety and tissue tropism advantages, with AAV2, AAV8, and AAV9 representing commonly referenced serotypes that differ in biodistribution and preexisting immunity considerations; Adenovirus provides high payload capacity and transduction efficiency for transient expression; Lentivirus and Retrovirus are foundational for durable, integrating approaches such as ex vivo cell therapies. These differences demand tailored manufacturing and analytical strategies that match molecular attributes to therapeutic intent.

Application segmentation underscores divergent development and manufacturing pathways. Cell Therapy, Gene Therapy, Research, and Vaccine applications have unique process and regulatory footprints. Within Cell Therapy, CAR T, Dendritic, and TCR T modalities pose specific vector dosing, potency assay, and safety testing needs. Gene Therapy divides into Ex Vivo and In Vivo approaches, each with differing vector purity and biodistribution requirements. Research applications span Basic Research and Preclinical Research, driving demand for flexible small-scale production and rapid turnaround, while Vaccine programs-both Prophylactic and Therapeutic-prioritize scalable, cost-efficient manufacturing and batch traceability.

Therapeutic area segmentation-Cardiovascular Disorders, Infectious Disease, Neurological Disorders, Oncology, and Rare Diseases-further refines prioritization. Cardiovascular programs split into coronary and peripheral vascular focuses with distinct delivery challenges; Infectious Disease divides into bacterial and viral targets that impact antigen design and immunogenicity management; Neurological Disorders separate into neurodegenerative and neurodevelopmental conditions that influence administration routes and safety monitoring; Oncology programs bifurcate into hematological and solid tumor strategies with differing cell targeting and tumor microenvironment considerations; Rare Diseases, often monogenic, demand highly individualized product strategies and flexible manufacturing capable of low-volume, high-complexity production.

End users-Biopharma Companies, Hospitals And Clinics, and Research Institutes-drive different demand profiles and service expectations. Biopharma companies often require integrated development and commercial scale solutions, hospitals and clinics emphasize parenteral formulation, cold chain logistics, and point-of-care readiness, while research institutes prioritize rapid access and methodological flexibility. Production stage segmentation between Downstream and Upstream highlights where investment in filtration, formulation, purification and cell expansion, harvesting, and transfection deliver the greatest operational leverage. Downstream purification, including chromatography and ultracentrifugation, remains a persistent bottleneck for purity and yield, whereas upstream improvements in cell expansion and transfection efficiency directly enhance vector productivity. Finally, production scale segmentation-Clinical and Commercial-reflects different operational cadences: clinical work requires nimble phase-specific manufacturing across Phase I, Phase II, and Phase III, while commercial full-scale operations emphasize reproducibility, cost of goods optimization, and long-term supply agreements.

Taken together, these segmentation layers provide a multidimensional map for prioritizing technology investments, partnership models, and manufacturing footprints based on therapeutic modality, target population, and commercialization pathway.

Regional dynamics shaping access, manufacturing strategy, and partnership models across the Americas, EMEA, and Asia-Pacific jurisdictions

Regional factors strongly influence strategic choices for viral vector development and deployment. In the Americas, established biotech clusters and advanced manufacturing networks support rapid translational pathways and access to specialized CDMOs, but program teams must also navigate regional regulatory expectations and reimbursement landscapes that affect commercialization strategies. In Europe, Middle East & Africa, regulatory harmonization efforts and diverse national health systems create both opportunities for cross-border collaboration and complexity for clinical trial design; here, partnerships with established local manufacturers and academic centers can streamline patient access while aligning to regional compliance frameworks. In the Asia-Pacific region, rapid expansion of GMP capacity, growing local scientific talent pools, and policy incentives for domestic biomanufacturing are accelerating capacity growth, though sponsors must carefully assess regional supply reliability and the implications of local content and intellectual property considerations.

Across these regions, clinical trial recruitment dynamics, prevalence of target indications, and payer evaluation criteria differ significantly, which informs where to site pivotal studies and how to structure market access strategies. Manufacturing location decisions are similarly sensitive to regional cost structures, talent availability, and proximity to patient populations. Given these variances, companies are increasingly adopting hybrid models that pair regional development hubs with distributed manufacturing to balance cost, regulatory alignment, and time to patient. Ultimately, regional strategy must be tightly integrated with product profiling, clinical design, and commercial access planning to ensure successful translation from development to widespread use.

Competitive and collaborative company insights that highlight capability clusters, partnership archetypes, and strategic priorities in the viral vectors ecosystem

Leading organizations in the viral vector space can be grouped by core capabilities: those focused on platform engineering and capsid discovery, providers specializing in scalable GMP manufacturing, and integrators offering end-to-end development support. Platform innovators prioritize deep molecular engineering, advanced analytics, and IP portfolios around serotype design and immune evasion strategies, typically supporting multiple clinical programs across therapeutic areas. Manufacturing specialists emphasize process robustness, high-yield upstream platforms, and downstream purification technologies that address persistent bottlenecks. Integrators and CDMOs bridge these capabilities, offering modular services that allow sponsors to accelerate clinical supply with predictable timelines and regulatory support.

Strategic partnerships are increasingly common, with technology licensors working alongside CDMOs and academic translational groups to de-risk early programs and to scale successful candidates. Companies are also competing on service breadth, geographic footprint, and the ability to manage complex comparability exercises. Investment in analytical development, digital batch records, and quality automation is a differentiator for organizations aiming to move from clinical to commercial supply. For executives assessing partners, alignment on quality culture, data transparency, and contingency planning for supply continuity are the most important indicators of long-term reliability.

Actionable recommendations that industry leaders should deploy now to secure development continuity, regulatory alignment, and commercial readiness for viral vector programs

Prioritize integrated early-stage planning that ties capsid selection, payload design, and manufacturing strategy to regulatory expectations. Embedding regulatory and quality experts into early program decisions reduces the risk of late-stage surprises and simplifies comparability when process changes become necessary. Concurrently, invest in analytical depth early to establish robust potency and impurity assays that will support both IND filings and future manufacturing transfers.

Strengthen supply chain resilience through dual sourcing of critical consumables and by qualifying regional suppliers to shorten lead times. Where feasible, adopt modular or single-use manufacturing elements to accelerate clinical supply without heavy capital commitments. For longer-term strategies, assess hybrid manufacturing footprints that combine regional clinical supply hubs with centralized commercial capacity to optimize cost and ensure patient access.

Negotiate partnership agreements that include clear quality metrics, data access provisions, and contingency clauses for supply disruptions. Finally, align commercial planning with clinical development by engaging market access and medical affairs early to define evidence generation needs and patient access pathways, thereby smoothing the transition from regulatory approval to real-world use.

Research approach and methodologies employed to produce robust, reproducible, and decision-grade insights across the viral vectors domain

This research synthesizes evidence from primary interviews with industry experts, qualitative analyses of regulatory guidance, and technical literature to triangulate the operational and strategic implications for viral vector development. Primary sources include subject matter experts across process development, analytical science, quality, and commercial functions, providing a composite view of process bottlenecks, technology adoption, and partnership behaviors. Secondary inputs draw on peer-reviewed studies, regulatory guidance documents, and public disclosures to ground technical descriptions and to validate observed industry trends.

Analytical rigor is achieved through cross-validation of qualitative insights with technical feasibility checks, for example correlating described upstream yields with downstream purification constraints to assess realistic process throughput. The methodology prioritizes transparency about evidence provenance, explicitly flagging where conclusions derive from consensus expert judgment versus established public documentation. Limitations and sensitivity considerations are noted throughout to support responsible interpretation and to guide areas for additional primary data collection where required.

Concluding synthesis that reaffirms strategic priorities and highlights the most consequential operational levers for viral vector success

The fundamental takeaway is that scientific advances alone will not guarantee program success; operational execution, regulatory foresight, and supply chain design are equally determinative. Success in viral vector programs depends on aligning vector selection and payload design with scalable manufacturing processes, embedding analytical rigor early, and structuring partnerships that offer both technical capability and supply continuity. Organizations that adopt modular manufacturing approaches, invest in deep analytical development, and proactively manage supplier risk will be better positioned to translate promising biological science into reliable clinical and commercial supply.

As the ecosystem matures, leaders should treat capability building as a strategic priority rather than an operational afterthought. This means committing resources to quality systems, process characterization, and strategic supplier relationships while maintaining flexibility to adapt to evolving regulatory expectations and geopolitical trade dynamics. In short, the path to durable value lies in marrying scientific innovation with disciplined operational practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in engineered adeno-associated virus capsids for targeted in vivo gene delivery
  • 5.2. Expansion of continuous bioprocessing platforms to increase viral vector manufacturing capacity
  • 5.3. Integration of single-use bioreactor technologies in scalable lentiviral vector production systems
  • 5.4. Emerging synthetic biology approaches for tunable promoter control in viral vector gene expression
  • 5.5. Strategic collaborations between CMOs and biotech firms to accelerate viral vector supply chain resilience
  • 5.6. Regulatory harmonization initiatives addressing global clinical trial approval for viral vector therapies
  • 5.7. Development of mRNA-encoding viral vectors for rapid vaccine response to novel infectious disease outbreaks
  • 5.8. Implementation of advanced analytics and AI-driven process monitoring in viral vector purification workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vectors Market, by Vector Type

  • 8.1. Adeno Associated Virus
    • 8.1.1. AAV2
    • 8.1.2. AAV8
    • 8.1.3. AAV9
  • 8.2. Adenovirus
  • 8.3. Lentivirus
  • 8.4. Retrovirus

9. Viral Vectors Market, by Application

  • 9.1. Cell Therapy
    • 9.1.1. Car T
    • 9.1.2. Dendritic
    • 9.1.3. TCR T
  • 9.2. Gene Therapy
    • 9.2.1. Ex Vivo
    • 9.2.2. In Vivo
  • 9.3. Research
    • 9.3.1. Basic Research
    • 9.3.2. Preclinical Research
  • 9.4. Vaccine
    • 9.4.1. Prophylactic
    • 9.4.2. Therapeutic

10. Viral Vectors Market, by Therapeutic Area

  • 10.1. Cardiovascular Disorders
    • 10.1.1. Coronary
    • 10.1.2. Peripheral Vascular
  • 10.2. Infectious Disease
    • 10.2.1. Bacterial
    • 10.2.2. Viral
  • 10.3. Neurological Disorders
    • 10.3.1. Neurodegenerative
    • 10.3.2. Neurodevelopmental
  • 10.4. Oncology
    • 10.4.1. Hematological
    • 10.4.2. Solid Tumor
  • 10.5. Rare Diseases
    • 10.5.1. Monogenic

11. Viral Vectors Market, by End User

  • 11.1. Biopharma Companies
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Viral Vectors Market, by Production Stage

  • 12.1. Downstream
    • 12.1.1. Filtration
    • 12.1.2. Formulation
    • 12.1.3. Purification
      • 12.1.3.1. Chromatography
      • 12.1.3.2. Ultracentrifugation
  • 12.2. Upstream
    • 12.2.1. Cell Expansion
    • 12.2.2. Harvesting
    • 12.2.3. Transfection

13. Viral Vectors Market, by Production Scale

  • 13.1. Clinical
    • 13.1.1. Phase I
    • 13.1.2. Phase II
    • 13.1.3. Phase III
  • 13.2. Commercial
    • 13.2.1. Full Scale

14. Viral Vectors Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Viral Vectors Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Viral Vectors Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Lonza Group AG
    • 17.3.3. Merck KGaA
    • 17.3.4. Catalent Inc.
    • 17.3.5. WuXi AppTec Co., Ltd.
    • 17.3.6. Novasep Holding SAS
    • 17.3.7. Oxford BioMedica plc
    • 17.3.8. AGC Biologics Inc.
    • 17.3.9. Cobra Biologics Ltd.
    • 17.3.10. Viralgen S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VIRAL VECTORS MARKET SIZE, BY MONOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 329. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 330. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL VIRAL VECTORS MARKET SIZE, BY CLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 334. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 340. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)

TABLE 346.